Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for preventing manmmal vagina infection and use

A technology for mammalian and vaginal infection, which is applied in the directions of drug combinations, active ingredients of hydroxy compounds, and medical preparations containing active ingredients, etc. The effect of strong microbial activity, small dose and unique mechanism of action

Inactive Publication Date: 2007-11-14
SINGSO BEIJING BIOLOGY SCI & TECH
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0018] The traditional treatment of infectious diseases of the genitourinary system mostly uses drugs such as antibiotics or metronidazole and hormones. Some of these drugs have toxic reactions; some can lead to the generation and spread of drug-resistant strains; The bacteria also kill the beneficial Lactobacillus, causing the imbalance of the flora and causing other diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Embodiment 1: Preparation of β-HPA

[0049] Production of β-HPA by Lactobacillus reuteri

[0050] 1. Cell preparation:

[0051] 1) Strain activation: Inoculate the bacterial cells of Lactobacillus reuteri (Lactobacillus reuteri CGMCC No.2046) in the MRS solid medium for 16 hours at 37°C, insert the solid activated bacteria into the liquid MRS, and activate once again at 37°C overnight .

[0052] 2) liquid culture cells: inoculate with 2% amount in containing 40mmol / L glycerol and 5mg / LVB 12 MRS liquid medium (pH6.5), anaerobic, 37 ° C for 16 h.

[0053] MRS medium

[0054] Tryptone 10g

[0055] Beef Extract 10g

[0056] Tween 80 1ml

[0057] Triammonium citrate 2g

[0058] Magnesium sulfate 0.5g

[0059] L-cysteine ​​0.5g

[0060] Glucose 20g

[0061] Yeast extract 5g

[0062] Dipotassium hydrogen phosphate 5g

[0063] Sodium acetate 10g

[0064] Manganese sulfate 0.2g

[0065] Sodium Thioglycolate 0.05g

[0066] Distilled water 1000ml

[0067] pH 6.5-7...

Embodiment 2

[0077] Embodiment 2: Preservation test of probiotics Lactobacillus reuteri and Clostridium butyricum

[0078] Cultivate the bacteria according to Example 1, and collect the bacteria by centrifugation, then add 2.7% glycerin, 8% skimmed milk powder, and 8.5% trehalose, stir well, freeze-dry for 24 hours, store in the refrigerator for 2 years, and take samples every 3 months to detect the bacteria The activity of producing β-HPA. The results showed that the vitality did not change much within 1 year, and the vitality dropped to 90% after 1.5 years, and 80% after 2 years, but still met the drug standard.

Embodiment 3

[0079] Embodiment 3: Preservation test of β-HPA

[0080] β-HPA was prepared according to Example 1. The experiment proved that the activity of β-HPA prepared from pure distilled water remained basically unchanged after being sealed and stored in a refrigerator for 2 years. Inhibition / killing ability is still very strong.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a medicine composition for curing human and animal vaginal infection. Said medicine composition includes probiotics capable of producing beta-hydroxy-propionaldehyde (beta-HPA), glycerine, beta-hydroxypropionaldehyde and natamycin. The invented medicine composition can inhibit and kill various vaginal pathogenic bacteria and fungi.

Description

technical field [0001] The present invention relates to compositions for the prevention and treatment of vaginal infections in mammals, including humans. Background technique [0002] 1. Lactobacillus reuteri and Clostridium butyricum and their metabolite β-HPA [0003] Lactobacillus reuteri and Clostridium butyricum are internationally recognized probiotics (M.Campieri 2005; Yang Guiping 1998; Li Xiongbiao 2006). It can be used not only as food, feed, but also as medicine, and has remarkable curative effect. The β-HPA produced by these two bacteria has important physiological functions. A large number of facts show that β-HPA can inhibit / kill Gram-positive and Gram-negative bacteria, yeasts, filamentous fungi, viruses, protozoa, etc. (Dohrogsz 1988, 1994, 2006; E.rodriguez 2003; S.Vollen weider 2004 ; Ganzle 2004; Pei Jiawei 2003). Its mechanism of action is to inhibit nucleic acid reductase, that is, inhibit DNA de novo synthesis. Gram-negative bacteria are most sensi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/74A61K9/00A61P17/02A61P15/02A61P13/00A61K31/047A61K31/11A61K31/7048A61K35/741A61K35/747
Inventor 郭兴华
Owner SINGSO BEIJING BIOLOGY SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com